

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 April 2023 (20.04.2023)



(10) International Publication Number
WO 2023/064363 A9

(51) International Patent Classification:

C07C 55/10 (2006.01) C07C 225/20 (2006.01)
C07C 59/255 (2006.01) C07D 275/06 (2006.01)

(21) International Application Number:

PCT/US2022/046412

(22) International Filing Date:

12 October 2022 (12.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/254,878 12 October 2021 (12.10.2021) US

(71) Applicant: PERCEPTION NEUROSCIENCE, INC.

[US/US]; 180 Varick Street, Floor 6, New York, New York
10014 (US).

(72) Inventors: JUMAA, Mouhannad; 5669 Trowbridge Way,

San Jose, California 95138 (US). KELLY, Terence Alfred;
41 Minuteman Rd., Ridgefield, Connecticut 06877 (US).

(74) Agent: PAVAO, Matthew et al.; Cooley LLP, 1299 Penn-
sylvania Ave. NW Suite 700, Washington, District of Co-
lumbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

(54) Title: R-KETAMINE SALTS AND METHODS OF USE THEREOF




FIG. 1

(57) Abstract: The present disclosure relates to novel salts and salt forms of (2R)-2-(2-chlorophenyl)-2- (methylamino)cyclohexa-
n-1-one (R-ketamine) and to processes for their preparation. The disclosure is also directed to pharmaceutical compositions containing at
least one R-ketamine 5 salt or salt form and to the therapeutic and/or prophylactic use of such salts, salt forms, and compositions thereof.

[Continued on next page]

LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

15 February 2024 (15.02.2024)

(15) Information about Correction:

see Notice of 15 February 2024 (15.02.2024)